Doxorubicin-DNA complex: a phase I clinical trial

Area of Science:

• Oncology
• Pharmacology

Background:

• Advanced malignancies present significant treatment challenges.
• Doxorubicin is a widely used chemotherapy agent, but its efficacy can be limited by toxicity.
• Novel drug delivery systems, such as doxorubicin-DNA complexes, are being investigated to improve therapeutic outcomes.

Purpose of the Study:

• To evaluate the safety and tolerability of doxorubicin-DNA complex in patients with advanced malignancies.
• To determine the maximum tolerated dose (MTD) and dose-limiting toxicities of doxorubicin-DNA complex.
• To assess preliminary clinical activity of doxorubicin-DNA complex.

Main Methods:

• A phase I clinical trial was conducted involving 35 patients with advanced malignancies.
• Doxorubicin-DNA complex was administered at doses ranging from 20 to 135 mg/m2.
• Patients were monitored for nonhematologic and hematologic toxicities, including ECG changes and granulocyte/platelet nadirs.

Main Results:

• The most frequent nonhematologic toxicities included nausea/vomiting (32%), fever/chills (24%), and mucositis (18%).
• Dose-limiting granulocytopenia was observed, with median granulocyte nadirs of 0.3 X 10(3)/microliter at 75 mg/m2.
• Clinical responses (complete + partial) were observed in 12% of patients, with 48% showing stable disease.

Conclusions:

• Recommended starting doses are 60 mg/m2 for patients with adequate bone marrow reserve and 50 mg/m2 for those with compromised marrow.
• Doxorubicin-DNA complex exhibits significant toxic effects on the gastrointestinal and hematopoietic systems.
• Further investigation is warranted to optimize the use of doxorubicin-DNA complex in cancer therapy.